Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

UBS Downgrades Quest Diagnostics to Neutral, Lowers Price Target to $139

UBS analyst Kevin Caliendo downgrades Quest Diagnostics (NYSE:DGX) from Buy to Neutral and lowers the price target from $160 to $139.

byBenzinga Newsdesk

February 23, 2022

1 minute read

UBS analyst Kevin Caliendo downgrades Quest Diagnostics (NYSE:DGX) from Buy to Neutral and lowers the price target from $160 to $139.

Loop Capital Maintains Buy on Academy Sports, Lowers Price Target to $43

By Benzinga Newsdesk

Today, 8:12 AM

Loop Capital analyst Daniel Adam maintains Academy Sports (NASDAQ:ASO) with a Buy and lowers the price target from $58 to $43.

ASO

News

LAIX Announces Receipt Of NYSE Non-Compliance Letter

By Benzinga Newsdesk

Today, 8:12 AM

LAIX Inc. ("LAIX" or the "Company") (NYSE:LAIX), an artificial intelligence (AI) company in China that creates and delivers products and services to popularize English learning, today

LAIX

Raymond James Maintains Strong Buy on Intercontinental Exchange, Lowers Price Target to $157

By Benzinga Newsdesk

Today, 8:12 AM

Raymond James analyst Patrick O'Shaughnessy maintains Intercontinental Exchange (NYSE:ICE) with a Strong Buy and lowers the price target from $161 to $157.

ICE